Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
Montaner JS, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, et al. Montaner JS, et al. Among authors: gill j. J Acquir Immune Defic Syndr (1988). 1994 Sep;7(9):924-30. J Acquir Immune Defic Syndr (1988). 1994. PMID: 7519674
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA. Montaner JS, et al. Among authors: gill j. Ann Intern Med. 1995 Oct 15;123(8):561-71. doi: 10.7326/0003-4819-123-8-199510150-00001. Ann Intern Med. 1995. PMID: 7677296 Clinical Trial.
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
Loutfy MR, Raboud JM, Montaner JS, Antoniou T, Wynhoven B, Smaill F, Rouleau D, Gill J, Schlech W, Brumme ZL, Mo T, Gough K, Rachlis A, Harrigan PR, Walmsley SL. Loutfy MR, et al. Among authors: gill j. Antiviral Res. 2007 Jul;75(1):58-63. doi: 10.1016/j.antiviral.2006.11.011. Epub 2006 Dec 18. Antiviral Res. 2007. PMID: 17196268
Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study.
Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. Klein MB, et al. Among authors: gill j. Int J Epidemiol. 2010 Oct;39(5):1162-9. doi: 10.1093/ije/dyp297. Epub 2009 Sep 28. Int J Epidemiol. 2010. PMID: 19786463 No abstract available.
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A, Vanveggel S, Boven K; ECHO and THRIVE Study Groups. Nelson M, et al. J Antimicrob Chemother. 2012 Aug;67(8):2020-8. doi: 10.1093/jac/dks130. Epub 2012 Apr 24. J Antimicrob Chemother. 2012. PMID: 22532465 Free PMC article. Clinical Trial.
HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality.
Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, Conway B, Cooper C, Côté P, Gill J, Haase D, Haider S, Hull M, Moodie E, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S; Canadian HIV-HCV Cohort Investigators. Klein MB, et al. Among authors: gill j. HIV Med. 2013 Jan;14(1):10-20. doi: 10.1111/j.1468-1293.2012.01028.x. Epub 2012 May 28. HIV Med. 2013. PMID: 22639840 Free article.
3,253 results